Education
About Us
Working with TipRanks
Follow Us
Revvity, Inc. (RVTY)
NYSE:RVTY
RVTY Stock Chart & Stats
$108.80
-$0.88(-0.75%)
At close: 4:00 PM EST
$108.80
-$0.88(-0.75%)
Day’s Range― - ―
52-Week Range$81.36 - $126.57
Previous CloseN/A
Volume176.09K
Average Volume (3M)1.13M
Market Cap
$12.34B
Enterprise Value$15.07B
Total Cash (Recent Filing)$931.39M
Total Debt (Recent Filing)$3.37B
Price to Earnings (P/E)54.4
Beta0.82
Next Earnings
May 04, 2026EPS Estimate
1.04Next Dividend Ex-DateN/A
Dividend Yield0.29%
Share Statistics
EPS (TTM)1.70
Shares Outstanding113,375,620
10 Day Avg. Volume1,360,071
30 Day Avg. Volume1,126,316
Financial Highlights & Ratios
PEG Ratio-3.33
Price to Book (P/B)0.00
Price to Sales (P/S)3.96
P/FCF Ratio21.97
Enterprise Value/Market Cap1.22
Enterprise Value/Revenue5.36
Enterprise Value/Gross Profit10.36
Enterprise Value/Ebitda19.57
Forecast
1Y Price Target
$111.14Price Target Upside2.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Biopharma R&D OutlookExposure to an improving biopharma R&D outlook could translate into stronger revenue and earnings as buybacks and cost controls enhance profitability.
Margin ImprovementA large cost-reduction program is expected to drive margin expansion, with management indicating margins for 2026 should improve as cost savings fully phase in.
Software Segment GrowthRobust performance in the Signals Software business and planned product launches position the company for sustained software-led revenue growth and higher-margin contributions.
Bears Say
China Diagnostics Regulatory RiskDRG policy headwinds in the China diagnostics business remain a significant overhang and could suppress revenue growth until policy impacts ease.
Life Sciences Segment WeaknessFlat organic revenue in Life Sciences and a decline in instrument sales point to softer demand within the Life Science Solutions portfolio.
Tariff And Timing HeadwindsNear-term earnings and margin pressure from tariff headwinds, calendar-related effects, and the timing of cost actions could weigh on profitability and share performance.
Revvity News
RVTY FAQ
What was Revvity, Inc.’s price range in the past 12 months?
Revvity, Inc. lowest stock price was $81.36 and its highest was $126.57 in the past 12 months.
What is Revvity, Inc.’s market cap?
Revvity, Inc.’s market cap is $12.34B.
When is Revvity, Inc.’s upcoming earnings report date?
Revvity, Inc.’s upcoming earnings report date is May 04, 2026 which is in 90 days.
How were Revvity, Inc.’s earnings last quarter?
Revvity, Inc. released its earnings results on Feb 02, 2026. The company reported $1.7 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.13.
Is Revvity, Inc. overvalued?
According to Wall Street analysts Revvity, Inc.’s price is currently Undervalued.
Does Revvity, Inc. pay dividends?
Revvity, Inc. pays a Quarterly dividend of $0.07 which represents an annual dividend yield of 0.29%. See more information on Revvity, Inc. dividends here
What is Revvity, Inc.’s EPS estimate?
Revvity, Inc.’s EPS estimate is 1.04.
How many shares outstanding does Revvity, Inc. have?
Revvity, Inc. has 113,375,620 shares outstanding.
What happened to Revvity, Inc.’s price movement after its last earnings report?
Revvity, Inc. reported an EPS of $1.7 in its last earnings report, beating expectations of $1.57. Following the earnings report the stock price went down -1.748%.
Which hedge fund is a major shareholder of Revvity, Inc.?
Currently, no hedge funds are holding shares in RVTY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Revvity Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$111.14 (2.15% Upside)
$111.14 (2.15% Upside)
Blogger Sentiment
Bullish
RVTY Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.3%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-13.97%
12-Months-Change
Fundamentals
Return on Equity
3.04%
Trailing 12-Months
Asset Growth
-4.94%
Trailing 12-Months
Company Description
Revvity, Inc.
Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
RVTY Company Deck
RVTY Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted clear operational resilience—EPS and cash flow beats, strong diagnostics and software momentum, major share repurchases, and strategic AI/software initiatives—offset by persistent end-market softness, China diagnostic weakness, margin pressure and a conservative 2026 growth outlook. Achievements (guidance beat, FCF strength, software traction, ACD acquisition, Signals Synthetica launch) are balanced by notable challenges (modest organic growth guidance, China DRG impacts, near-term margin headwinds, rising below-the-line costs), resulting in a cautious but constructive tone.View all RVTY earnings summariesRVTY Revenue Breakdown
45.52% Life sciences
54.48% Diagnostics
RVTY Stock 12 Month Forecast
Average Price Target
$111.14
▲(2.15% Upside)